Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Idiopathic Pulmonary Fibrosis
Sort By
Newest First
1 / 1
1 / 1
FDA Orphan Drug Designation
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
Pliant Therapeutics
PR-M08-18-NI-058
Aug 15, 2018
